Cetuximab
Small Intestine Leiomyosarcoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Small Intestine Leiomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gdc-0449 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Irinotecan National Cancer Institute (NCI) | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
rg4733 National Cancer Institute (NCI) | Phase 1/2 | CC |
EF-5 National Cancer Institute (NCI) | N/A | D |
LUTETIUM TEXAPHYRIN National Cancer Institute (NCI) | N/A | D |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →